Clinical trials for Nonalcoholic steatohepatitis investigate a range of treatment strategies and patient populations.

16 total trials for this combination

Showing top 10 of 16 trials

Trials

NCT ID	Title	Status	Phase
NCT02815891	A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)	RECRUITING	—
NCT03053063	Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)	TERMINATED	PHASE3
NCT04971785	Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)	COMPLETED	PHASE2
NCT03449446	Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)	COMPLETED	PHASE2
NCT03059446	Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis	TERMINATED	PHASE2
NCT03439254	Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis	COMPLETED	PHASE3
NCT02217475	Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis	COMPLETED	PHASE2
NCT03028740	AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)	TERMINATED	PHASE3
NCT03053050	Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis	TERMINATED	PHASE3
NCT03486912	A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis	COMPLETED	PHASE2

Related Pages

All Nonalcoholic steatohepatitis trials All trials in Baltimore, United States